"MTPA’s Radicava shows long-term benefit in ALS trials" was originally created and published by Clinical Trials Arena, a ...

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that causes the gradual loss of motor neurons in the brain and spinal cord, leading to muscle weakness, paralysis, and ...

Neurizon Therapeutics has reported positive topline results from an open-label extension study of its lead candidate NUZ-001 ...

GetNews Press Release.DelveInsight’s “ Amyotrophic Lateral Sclerosis (ALS) – Pipeline Insight, 2025 ” offers a detailed analysis of the evolving therapeutic landscape for ALS, a fatal ...

Jodi O’Donnell-Ames founded Hope Loves Company to provide support, resources, and community to children affected by ALS.

Yet another biotech is facing a delay from the FDA as the agency reels from intense staffing cuts. | Yet another biotech is ...

Family, friends and colleagues braved the heat early Friday evening to pay respect to the late Brent McGee, the former ...

Summary: A new study has uncovered why some motor neurons resist degeneration in ALS while others succumb. Researchers found ...

The ALS therapy ATH-1105 entered the brain and spinal cord at dose-proportional levels in healthy volunteers, and had a good ...

By analyzing millions of messenger RNA molecules (mRNA) during the course of ALS, researchers at Stockholm University, in ...

SineuGene gets China NMPA & US FDA nods to initiate phase I/IIa trial of gene therapy, SNUG01 to treat amyotrophic lateral sclerosis: Beijing Monday, August 18, 2025, 18:00 Hrs [I ...

The U.S. Food and Drug Administration has approved the ketamine product, KETARx, for use in surgical pain management.